New calculator predicts risk of early recurrence in patients with hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is the most commonly diagnosed cancer of the liver and the fourth leading cause of cancer-related mortality worldwide, with China accounting for over half of the global annual cases and deaths.

Ranibizumab biosimilar by Generium for Wet (Neovascular / Exudative) Macular Degeneration: Likelihood of Approval

Ranibizumab biosimilar is under clinical development by Generium and currently in Phase III for Wet (Neovascular / Exudative) Macular Degeneration. According to GlobalData, Phase III

August 30, 2023

Study sheds light on how traumatic memories are created

Scientists have long speculated about the physical changes that occur in the brain when a new memory is formed. Now, research from the National Institute

October 12, 2023

Coherus plans Humira biosimilar sale at 85% discount – Pharmaceutical Technology

Humira was AbbVie’s blockbuster drug with sales of $21.2bn in 2022. Credit: Coherus BioSciences. Coherus BioSciences has signed a US national distribution agreement with speciality

July 14, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.